Previous 10 | Next 10 |
home / stock / biovf / biovf news
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2019 Earnings Conference Call October 31, 2019, 05:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Milan Zdravkovic - Head of Research & Development and Chief Medical Officer Conference Call Participant...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2019 Q3 earnings Read more ...
STOCKHOLM , Oct. 31, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2019. Revenue growth in the quarter was 27 per cent with revenue of SEK 2,930 M (2,315). EBITA was SEK 1,099 M , resulting in an EBITA margin ...
STOCKHOLM , Oct. 23, 2019 /PRNewswire/ -- On 31 October, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presenta...
Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...
Merger activity increased last week with five new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will ...
Dova Pharmaceuticals (NASDAQ: DOVA ) is up 38% premarket after entering into an agreement and plan of merger with Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) (Sobi). More news on: Dova Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB (publ), Healthcare stocks news, Stocks o...
STOCKHOLM , Sept. 30, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 p...
Endo International (NASDAQ: ENDP ) is up 3% premarket on light volume in reaction to the FDA nod for subsidiary Endo Ventures partner's Novitium Pharma's generic version of Swedish Orphan Biovitrum's ( OTCPK:BIOVF ) Orafin (nitisinone capsules) for the treatment of hereditary t...
The FDA has signed off on Seelos Therapeutics' ( SEEL +7.3% ) IND for a Phase 2b/3 clinical trial evaluating SLS-005 (trehalose) in patients with mucopolysaccharidosis type III (Sanfilippo syndrome), an inherited disorder characterized by delayed speech and behavioral problems that is ...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Swedish Orphan Biovitrum AB (BIOVF) is expected to report $0.09 for Q3 2023